Kyowa Kirin Announces Launch of Darbepoetin Alfa Injection Syringe[KKF] in Japan
July 29, 2019
Tokyo, Japan, July 29, 2019 --- Kyowa Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Masashi Miyamoto, "Kyowa Kirin") announces today that its wholly owned subsidiary Kyowa Kirin Frontier Co., Ltd. (President and CEO: Ken Unemoto, "Kyowa Kirin Frontier") will launch "Darbepoetin Alfa Injection Syringe [KKF]" in Japan on August 5.
"Darbepoetin Alfa Injection Syringe [KKF]" which was approved in Japan on August 15, 2018, is an "Authorized version*1" of NESP®. Kyowa Kirin Frontier was established in January 2017 as part of "CSV*2 management based on unique business structure" within the "Contribution to Health and Well-being of People," which is one of the core strategies set forth by Kyowa Kirin in the current Mid-term Business Plan. Kyowa Kirin Frontier will conduct sales & marketing activities through co-promotion with Kyowa Kirin.
"We are delighted to announce this great news," said Ken Unemoto, President of Kyowa Kirin Frontier. "Through this product, we will contribute to the CKD patients and healthcare professionals in Japan to fulfill the role and responsibility as one of Kyowa Kirin Group members."
The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
- *1:Authorized version:
Kyowa Kirin has defined "Authorized version" as an identical drug with the same active pharmaceutical ingredients, excipients and manufacturing method as the branded drug and is manufactured and marketed by a company that has received the right to exploit the branded drug’s patent from the company which owns the patent. - *2:Creating Shared Value
CSV is the abbreviation of "Creating Shared Value." It refers to realizing improved corporate value by bringing about both the "creation of social value" and "creation of economic value" through efforts to address the pressing problems in society.
